Dr. Tomohiro KONNO was born in 1975 (Tokyo Japan). He received his PhD degree from The University of Tokyo in 2003, where he studied on amphiphilic water-soluble phospholipid polymers as colloid biomaterials. He then began an academic career at Kanagawa Academy of Science and Technology as a Researcher, and studied until 2005 in the development of polymeric biomaterials for regenerative medicine. In 2005, he moved to the Department of Materials Engineering, The University of Tokyo as Research Aassociate, and then transferred to Assistant Professor in 2007, where he studied on the cytocompatible polymer biomaterials particularly soft-biomaterials (e.g. polymer aggregates and reversible polymer hydrogels based on inter-molecular interction). In 2009, he promoted to Project Associate Professor at Department of Bioengineering, where he presided the Advanced Biodevice Engineering Laboratory which is a social cooperation program, where he studied on nanobio-technology related on a single cell analysis system. And then he transferred to the Educational Program for Human Resources for Advanced Medical Engineering at Department of Bioengineering in 2012, where he worked at an educational program for multi-disciplinary bioengineering field. In 2017, he transferred to Graduate Program for Leaders in Life Innovation (GPLLI), which the program is a cross-field educational program engaged to school of medicine, engineering, pharmaceutical sciences, and science. In 2018, he transferred to another interdisciplinary program, world-leading innovative graduate study program for life science and technology (WINGS-LST), where he worked in a multi-disciplinary biomedical, healthcare, and life science field.

In October 2018, he has been appointed Professor of Graduate School of Pharmaceutical Sciences, Tohoku University [Laboratory of Biointerface Chemistry, Department of Biophysical Chemistry (Major: Molecular Pharmaceutical Science)]. His current research interests include 1) polymer biomaterials science and engineering for pharmaceutical applications and advanced implantable medical devices, and 2) Colloid biomaterials and biointerfaces for cell engineering, regenerative medicine, nanomedicine, and precision/personalized medicine.